A patient with recalcitrant oral pemphigus vulgaris successfully treated with a biologic drug- Rituximab
Pemphigus vulgaris (PV) is a chronic autoimmune blistering disease affecting mucous membranes and the skin. Rituximab (RTX), a monoclonal antibody against CD20, has been approved by FDA for the treatment of adults with moderate to severe PV. A 42-year-old Indian woman, previously diagnosed with oral...
Shranjeno v:
| Main Authors: | , , |
|---|---|
| Format: | Online |
| Jezik: | angleščina |
| Izdano: |
International Association for Dental Research (Nigeria Division)
2019
|
| Online dostop: | https://ajoh.oauife.edu.ng/index.php/ajoh/article/view/41 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|
Komentirajte kot prvi!